ProMIS Neurosciences Secures $30.3 Million to Advance Alzheimer’s Therapy

Introduction

ProMIS Neurosciences Inc (Nasdaq: PMN) is a clinical-stage biotechnology company founded in 2015 and headquartered in Cambridge, Massachusetts, and Toronto, Ontario. The company utilizes its proprietary EpiSelect™ platform, which is based on computational protein-folding predictions, to identify disease-specific epitopes on toxic misfolded proteins associated with neurodegenerative disorders.

Corporate Structure

ProMIS Neurosciences employs between 2 and 10 people. Leadership includes Neil K. Warma, President and Chief Executive Officer since January 2024; Neil Cashman, M.D., Chief Scientific Officer and Co-founder; Johanne Kaplan, Ph.D., Chief Development Officer; and Larry Altstiel, M.D., Ph.D., Chief Medical Officer. The management team has experience from various biopharmaceutical companies, including Genexine, I-Mab Biopharma, Novartis, and Sanofi Genzyme, as well as academic institutions such as the University of Toronto and the University of British Columbia.

Neurodegenerative Therapy by Milad Fakurian

Recent Developments and News

On July 26, 2024, ProMIS entered a private placement agreement to issue common share units and pre-funded units, raising $30.3 million upfront at $2.15 per unit, with up to an additional $92.4 million tied to the exercise of warrants. The net proceeds are allocated for advancing PMN310, its lead anti-oligomer antibody candidate for Alzheimer’s disease, through multiple ascending-dose cohorts.

Dosing of Alzheimer’s patients in the Phase Ib PRECISE-AD trial began in 2024. The company anticipates reporting interim data at six months in the first half of 2026 and topline results at 12 months in the second half of 2026.

On May 15, 2025, Armistice Capital, LLC and Steven Boyd amended Schedule 13G/A to disclose beneficial ownership of 2,334,826 shares, representing approximately 7.14% of outstanding common stock. Form 8-K reports filed on June 13 and July 7, 2025, covered management changes, matters submitted for shareholder vote, and the furnishing of financial statement exhibits.

Financial and Strategic Analysis

As of July 21, 2025, PMN shares closed at $1.32, reflecting a 199.93% increase from the previous close, with a volume of approximately 36 million shares. The 52-week trading range spans $0.38 to $2.20. ProMIS’s market capitalization is supported by a share count of roughly 32.7 million.

The company employs equity-based financings and warrants to fund its clinical pipeline, indicative of the capital-intensive nature of antibody development. The EpiSelect™ platform differentiates ProMIS by focusing on conformational epitopes on toxic oligomers, positioning the company in a specialized field of precision neurodegenerative therapeutics.

Market Position and Industry Context

ProMIS operates within the competitive landscape of neurodegenerative disease therapeutics, where numerous biotechnology and pharmaceutical firms pursue antibody-based approaches for Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson’s disease, and related disorders. The emphasis on toxic oligomers distinguishes ProMIS from therapies targeting aggregated plaques or monomeric species. The company engages with investors through events such as the BIO CEO & Investor Conference in New York City and the Guggenheim SMID Cap Biotech Conference, as well as through webcast presentations to institutional audiences.

tl;dr

ProMIS Neurosciences raised $30.3 million on July 26, 2024, with potential to increase to $122.7 million via warrant exercises to support PMN310’s Phase Ib PRECISE-AD trial. Dosing began in 2024, with six-month interim data expected in H1 2026 and 12-month topline results in H2 2026. As of July 21, 2025, shares traded at $1.32 on Nasdaq, and Armistice Capital holds 7.14% of outstanding stock.